FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Fecal Microbiota Transplantation Combined With SOX and Sintilimab as First-line Treatment for Advanced Gastric Cancer:A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study (FMT-JSNO-01)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06405113
• Other study ID #: [2024]YLJSA001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2024
• Est. completion date: June 1, 2027

Study information

• Verified date: May 2024
• Source: Changzhou No.2 People's Hospital
• Contact: Hua Jiang, MD
• Phone: 86-18015852711
• Email: czeyjh[@]njmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We plan to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study, recruiting 198 patients with advanced gastric/gastroesophageal junction adenocarcinoma who have not received prior treatment. Randomly divided into two groups, one group is the group of fecal microbiota transplantation(FMT)+SOX+Sintilimab, and the other group is the group of SOX+Sintilimab. Compare the 2-year OS rates of the two groups to verify whether the addition of FMT to first-line treatment can improve the prognosis of gastric cancer patients.

Description:

We plan to initiate a prospective, multicenter randomized, double-blind, placebo-controlled phase II study, recruiting a total of 198 patients with previously untreated unresectable advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in our hospital and 14 other hospitals. Randomly divided into Group A and Group B, Group A received FMT+SOX chemotherapy regimen +Sintilimab immunotherapy regimen, Group B only received SOX chemotherapy regimen+and Sintilimab immunotherapy regimen. If there is no progression of the disease after 4-6 cycles of first-line treatment, both groups of patients will enter the first-line maintenance treatment stage: S-1+Sintilimab, until disease progression, intolerance, or death occurs. The aim is to explore the efficacy and safety of FMT combined with SOX and Sintilimab in the treatment of advanced first-line gastric cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 198
• Est. completion date: June 1, 2027
• Est. primary completion date: June 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subjects aged 18-80 (including 18 and 80 years old);

• Understand the research steps and content, and voluntarily sign a written informed consent form;

• Non resectable Her-2 negative advanced or metastatic gastric/gastroesophageal junction adenocarcinoma confirmed by histopathology and/or cytology, excluding all other histological types;

• At least one measurable lesion, according to RECIST 1.1 standard;

• Have not received anti-tumor treatment in the past;

• The physical status score of Eastern Tumor Collaboration Group (ECOG) was 0-1;

• Expected survival time = 3 months;

• Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements (no blood components, cell growth factors, albumin or other corrective drugs are allowed within 14 days prior to obtaining laboratory examination), as follows: 1) Blood routine: absolute neutrophil count (ANC) =1.5×109/L, platelet (PLT) =75×109/L, hemoglobin (HGB) =90 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: serum total bilirubin (TBIL) =2 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 5x ULN, serum albumin =28 g/L; alkaline phosphatase (ALP) =5×ULN; 3) Renal function: serum creatinine (Cr) =1.5×ULN, or creatinine clearance =50 mL/min (using the standard Cockcroft-Gault formula) : Urine routine results showed urinary protein < 2+; For patients with urine protein =2+ at baseline,24-hour urine collection and 24-hour urine protein quantification<1g should be performed; 4) Coagulation function: International standardized ratio (INR) or prothrombin time (PT) =1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as the INR is within the intended range of anticoagulant drug use.

• For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration;

• Subjects and their sexual partners are required to use a medically approved contraceptive method (such as an IUD, contraceptive pill, or condom) during the study treatment period and for 6 months after the end of the study treatment period.

Exclusion Criteria:

• Currently participating in an interventional clinical study or receiving another investigational drug or investigational device within 4 weeks prior to initial dosing;

• Received proprietary Chinese medicines with anti-tumor indications or immunomodulatory drugs (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration, or received major surgical treatment within 3 weeks before the first administration;

• Class III - IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmias;

• Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before treatment;

• Known allergic reaction to the drug in this study;

• Patients requiring long-term systemic use of corticosteroids. Patients with COPD or asthma requiring intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroids could be enrolled;

• Symptomatic central nervous metastases. Patients with asymptomatic BMS or BMS whose symptoms are stable after treatment are eligible to participate in this study if they meet all of the following criteria: measurable lesions outside the central nervous system; No midbrain, pontine, cerebellum, meninges, medulla oblongata or spinal cord metastasis; Maintain clinical stability for at least 2 weeks;

• Stop hormone therapy 3 days before the first dose of the study drug;

• There is an active infection requiring treatment or systemic anti-infective drugs have been used in the week prior to the first dosing;

• Has not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e., = grade 1 or baseline, excluding weakness or hair loss);

• Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody positive);

• Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greater than the upper limit of normal value in the laboratory of the study center);

• Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);

• Pregnant or lactating women;

• Medical history or evidence of disease that may interfere with test results, prevent participants from fully participating in the study, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment The Investigator considers other potential risks unsuitable for participation in the study.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Combination Product:
• Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Changzhou No.2 People's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year overall survival rate(2year-OS Rate)	The proportion of patients who have not died after 2 years of treatment	up to 24 months
Secondary	Median Progression-Free Survival (mPFS)	Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment.	up to 24 months
Secondary	Objective Response Rate (ORR)	Objective response rate will be assessed by investigators.	up to 24 months
Secondary	Incidence of Adverse events (AEs)	Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).	up to 24 months
Secondary	The Diversity of Fecal Microbiota	This will be detected by 16s rRNA sequencing or metagenomes.	up to 24 months
Secondary	Quality of Life (QoL)	QoL will be evaluated by EORTC-QLQ-C30.	up to 24 months